Ticagrelor with or without Aspirin in High-Risk Patients after PCI

In this placebo-controlled trial, 7119 patients were randomly assigned at 3 months after PCI to either receive ticagrelor alone or continue dual therapy with ticagrelor plus aspirin. The trial evaluated bleeding and ischemic end points at 1 year.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 381; číslo 21; s. 2032 - 2042
Hlavní autoři:	Mehran, Roxana, Baber, Usman, Sharma, Samin K, Cohen, David J, Angiolillo, Dominick J, Briguori, Carlo, Cha, Jin Y, Collier, Timothy, Dangas, George, Dudek, Dariusz, Džavík, Vladimír, Escaned, Javier, Gil, Robert, Gurbel, Paul, Hamm, Christian W, Henry, Timothy, Huber, Kurt, Kastrati, Adnan, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell, Kunadian, Vijay, Marx, Steven O, Mehta, Shamir R, Moliterno, David, Ohman, E. Magnus, Oldroyd, Keith, Sardella, Gennaro, Sartori, Samantha, Shlofmitz, Richard, Steg, P. Gabriel, Weisz, Giora, Witzenbichler, Bernhard, Han, Ya-ling, Pocock, Stuart, Gibson, C. Michael
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 21.11.2019
Témata:	Acute coronary syndromes Aged Antiplatelet therapy Aspirin Aspirin - adverse effects Aspirin - therapeutic use Bleeding Cardiovascular disease Cerebral infarction Coronary Disease - drug therapy Coronary Disease - therapy Coronary vessels Diabetes Double-Blind Method Drug Therapy, Combination Female Health risk assessment Heart attacks Hemorrhage Hemorrhage - chemically induced Humans Inhibitor drugs Ischemia Kaplan-Meier Estimate Male Middle Aged Mortality Myocardial infarction Myocardial Infarction - epidemiology Percutaneous Coronary Intervention Pharmaceuticals Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Risk Factors Risk groups Stents Stroke Stroke - epidemiology Ticagrelor - adverse effects Ticagrelor - therapeutic use
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	In this placebo-controlled trial, 7119 patients were randomly assigned at 3 months after PCI to either receive ticagrelor alone or continue dual therapy with ticagrelor plus aspirin. The trial evaluated bleeding and ischemic end points at 1 year.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1908419